Alzheimer’s disease remains the cornerstone of the market, holding the largest share of global revenues. Its high prevalence and significant unmet clinical need make it the primary focus for research investments and new therapeutic commercialization.
Eli Lilly secured FDA approval for donanemab, an anti-amyloid antibody. This is considered a major milestone as it marks a definitive shift in the industry from providing mere symptomatic relief toward disease-modifying therapies that target the underlying pathology of Alzheimer’s.
AI is being used to accelerate the discovery of new compounds, such as glutamate-modulating treatments. For example, Novartis entered a multi-year agreement in February 2025 with an AI-driven biotech company to use computational biology to shorten clinical trial timelines and reduce R&D risks.
Cholinesterase inhibitors remain relevant as frontline symptomatic treatments because they are more affordable and carry lower clinical risks than newer biologics. They are particularly vital in developing economies where healthcare budgets for neurodegenerative care may be limited.
Recognizing that single-pathway drugs often yield limited results, the industry is moving toward multi-mechanism formulations. These therapies target multiple areas simultaneously—such as NMDA receptors and amyloid plaques—to provide a more holistic management of the disease's complex pathophysiology.
The Asia-Pacific region is the fastest-growing market. This growth is driven by rapidly ageing populations in countries like China, India, and Japan, alongside increased government investment in neuroscience and healthcare infrastructure.
The market is characterized by excessively high R&D costs and high attrition rates during clinical trials. The complexity of dementia’s pathophysiology often leads to repeated trial failures, which can be financially devastating for smaller firms without significant backing.
NMDA receptor antagonists, such as memantine-based formulations, are increasingly used as auxiliary or adjunct therapies alongside cholinesterase inhibitors. They help modulate glutamatergic neurotransmission and are becoming a key component of multi-targeted combination regimens.
The industry is developing Mechanism-of-Action (MOA) targeted drugs that utilize biomarkers and genetic profiling. These precision therapies allow for personalized treatment approaches for specific niches like FTD, offering new opportunities for specialized biotech players.
